（文章来源：证券日报） 证券日报网讯 2月12日，瑞普生物发布公告称，持股5%以上股东梁武于2026年2月10日将280万股质押 给国金证券用于偿还债务，占其持股11.96%；同日解除质押430万股，占其持股18.37%。质押后梁武累 计质押880万股，占其持股37.60%。 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-004 瑞普生物股份有限公司 关于持股 5%以上股东梁武部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司"）近日接到持股 5%以上股东梁 武先生的函告，获悉梁武先生所持有公司的部分股份办理了质押及解除质押手续， 具体事项如下： 一、股份质押的基本情况 | 是否为控 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 股股东或 本次质押 占其所 占公司 股东 | 是否 | 是否为 | | | | 质押 | | 第一大股 股份数量 持股份 总股本 名称 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | 东及一致 （股） 比例 比例 | 售股 | 押 | | | | | | 行动人 | | | | | | | | 梁武 否 2,800,000 11.96% 0.60% | 否 | 否 | 2026/02/10 | 2029/02/07 | ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-002 1、本次拟投资设立的合伙企业尚需办理工商登记和基金备案手续，具体实 施情况与进度尚存在不确定性。 2、并购产业基金具有周期长、流动性低的特性，本次投资可能面临回收期 较长、短期难以为公司贡献利润的风险。 3、本次投资还可能受宏观经济、行业周期、监管政策及标的公司经营管理 等多重因素影响，存在未能实现预期收益、无法及时有效退出甚至投资失败的风 险。 4、本次投资事项为关联方共同投资，不涉及同业竞争，不构成重大资产重 组。 一、概述 瑞普生物股份有限公司 关于与专业投资机构共同投资设立并购产业基金 暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 其他合作方海通并购资本、海通开元投资、高邮产业引导基金与公司及公司 控股股东、实际控制人、持股 5%以上的股东、董事、高级管理人员均不存在关 联关系或其他利益安排。截至本公告披露日，上述合作方未以直接或间接方式持 有公司股份。 瑞晟私募为公司董事长李守军先生、董事李睿女士间接控制的企业，李睿女 士担任瑞晟私募董事长、经理。 ...

瑞普生物股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东会召开的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： 证券代码：300119 证券简称：瑞普生物 公告编号：2026-003 （1）现场会议时间：2026 年 3 月 3 日（星期二）14:30 （2）网络投票时间为：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 3 月 3 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 3 月 3 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 （1）现场投票：包括本人出席及 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-001 瑞普生物股份有限公司 第六届董事会第二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 1 产业基金暨关联交易的公告》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 关联董事李守军、李睿在审议本议案时回避表决。 本议案已经公司第六届董事会战略委员会第一次会议及独立董事 2026 年第 一次专门会议审议通过，尚需提交公司 2026 年第一次临时股东会审议。 2、审议通过了《关于召开 2026 年第一次临时股东会的议案》 瑞普生物股份有限公司（以下简称"公司"）第六届董事会第二次（临时） 会议于 2026 年 2 月 12 日在公司会议室以现场结合通讯表决方式召开。会议通知 于 2026 年 2 月 9 日以书面及电子邮件等方式送达全体董事。公司应出席董事 9 人，实际出席董事 9 人（其中：独立董事王凯以通讯方式参会），参与表决董事 9 人。本次会议由董事长李守军先生主持，公司高级管理人员列席了会议。本次 会议的召集、召开和表决程序符合 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

Investment Rating - The overall investment rating for the agriculture industry is "Positive" [6][10]. Core Insights - The report emphasizes the importance of agricultural investment opportunities following the release of the central government's No. 1 document, which highlights the need for comprehensive capacity regulation in the pig farming industry [5][19]. - The report identifies potential investment opportunities in the livestock and planting sectors, particularly focusing on companies with low valuations and strong growth potential [6][10]. Summary by Relevant Sections Livestock Industry - **Pig Farming**: The average price for pigs is 12.14 CNY/kg, a slight decrease of 0.16 CNY from the previous week. The average price for piglets is 29.24 CNY/kg, which increased by 0.62 CNY [5][19]. The industry is experiencing a gradual reduction in production capacity, with the number of breeding sows decreasing by 2.9% year-on-year [6][20]. - **Chicken Farming**: The average price for broiler chickens is 14 CNY/kg, reflecting a 0.3 CNY increase. However, the industry is facing challenges with profitability, as the average loss per chicken is 0.26 CNY [21][22]. The report suggests that chicken prices may remain volatile in the medium term due to high production levels [21][22]. - **Investment Recommendations**: Companies such as Zhongchong Co., Muyuan Foods, and Suqian Agricultural Development are rated as "Buy" due to their strong market positions and growth potential [3][10]. Planting Industry - **Seed Industry**: The No. 1 document promotes the industrialization of biotechnology in agriculture, which is expected to enhance the seed supply chain and improve the market environment for genetically modified crops [11][23]. The report gives a positive rating for the seed industry, highlighting the long-term investment value of leading companies [11][23]. - **Grain Prices**: Recent trends indicate that grain prices are likely to continue rising due to increased demand and reduced supply. The average price for corn is 2394 CNY/ton, and for wheat, it is 2531 CNY/ton, both showing slight increases [12][24]. The report suggests focusing on investment opportunities in the planting sector, particularly in companies like Suqian Agricultural Development [12][24].

Core Insights - The report titled "2026-2032 China Pet Industry Panorama Survey and Market Assessment" provides essential reference for decision-makers and investors in the pet industry, based on comprehensive analysis and interviews with industry experts and executives [1][4]. Industry Overview - The pet industry in China is transitioning from "rapid growth" to "high-quality development," with a shift in the role of pets from mere companions to emotional partners [8][10]. - The market for exotic pets (reptiles and aquatic pets) is rising, with a significant increase in the population of amphibians and reptiles expected [8]. - By 2026, the number of pets in China is projected to grow by 5.5% year-on-year, while the overall market size is expected to increase by 9.5% [10]. Market Dynamics - The pet industry has entered an era of "refined pet-keeping," characterized by an expanding market size and a shift towards high-end and emotional consumption [10]. - Challenges such as standardization, talent shortages, and economic fluctuations are present, but opportunities arise from technological empowerment, globalization, and policy support [10]. Historical Context - The development of the pet industry in China began in the early 1990s and has undergone various phases, including an enlightenment phase, a nurturing phase, and is now entering a high-speed development phase starting from 2025 [13][14]. - Changes in family structures, such as the increase in empty-nest and DINK families, along with rising income levels and improved consumption structures, are driving the growing demand for pets [13]. Data Collection Methodology - The report's data accuracy is ensured through multiple channels, including annual reports from listed companies, manufacturer surveys, dealer discussions, and expert validations, utilizing a proprietary industry analysis model [4][10]. Future Trends - The report anticipates that pets will increasingly be viewed as family members and emotional companions, driving the industry towards high-quality development [10]. - The pet industry is expected to see a rise in the variety of pet species and a flourishing pet services sector, with a trend towards down-market consumption [27].

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and technological advancements, positioning it as a key future industry in China [1][2] - The market size of China's biomanufacturing industry is projected to reach approximately 1.8 trillion yuan by 2030, with significant contributions from food additives and biopharmaceuticals [1][2] Industry Developments - The Ministry of Industry and Information Technology has reported that during the 14th Five-Year Plan, China's biomanufacturing industry is expected to expand steadily, reaching a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The focus of the 14th Five-Year Plan is on the industrialization of technology, emphasizing pilot testing, process scaling, and demonstration line construction [2] Company Initiatives - Ruipu Biotech is investing 680 million yuan in a large-scale microbial protein industrialization demonstration project, aiming for trial production by Q4 2026 [3] - Fuxiang Pharmaceutical is leveraging its expertise in high-end antibiotic fermentation to enhance its microbial protein project, focusing on domestic and international expansion [4] - Yikela Biotech is targeting high-value aquatic feed proteins through a collaboration with Fudan University, aiming to reduce reliance on imported fishmeal [5] Technological Advancements - Synthetic biology is identified as a core technology driving low-carbon production and increased labor productivity across various sectors, including healthcare and industrial manufacturing [2] - The integration of AI with synthetic biology is expected to shift the competitive landscape from single-point breakthroughs to platform-based competition, enhancing R&D efficiency [7] Market Trends - The most promising sub-sectors in biomanufacturing during the 14th Five-Year Plan include high-value biomanufactured products in healthcare, bio-based materials, and service-oriented platforms [6] - The industry is anticipated to experience differentiation and improved quality as companies focus on scalable processes, cost control, and clear downstream applications [2][6]